PubMed HealthSearch

PubMed · 9234310

Immunoassay: recent developments and future directions.

Abstract

All analytical techniques employed in the biological sciences rely on recognition of the shape and structure of molecules of the substance of interest (the analyte). Such molecular recognition and sensing usually relies on the use other molecules possessing a complementary structure, implying a specific lock and key relationship between the two. Antibodies comprise a class of recognition molecules evolved by nature for the purpose of bodily defence, and are clearly of particular utility in this context. However techniques of increasing sophistication (including the techniques of molecular biology) are currently being developed which enable the artificial construction of antibody-like molecules possessing improved molecular recognition properties which can be harnessed for microanalytical purposes. Oligonucleotide probes likewise exhibit the property of binding to complementary nucleotide sequences, and the techniques of, for example, in situ hybridisation therefore share many features with immunoassay techniques. Microanalytical techniques relying on binding reactions between substances possessing complementary lock and key molecular structures are unlikely to be superseded within the foreseeable future, only the labels used to monitor such reactions, and the means of production of "recognition molecules", being subject to further development. Such techniques already enter into all areas of life, including medicine, agriculture, etc, and are likely to increase further in importance with increasing concern regarding chemically complex contaminants in food, the environment, etc. Developments in this field are clearly directed to slightly differing objectives as indicated in this presentation. These include methodological simplification (making the techniques cheaper and more widely available), improvements in sensitivity (to enable the detection and measurement of substances beyond the reach of current methods) and the construction of transducer-based sensor methods (permitting, inter alia, the monitoring of changing analyte concentrations). However the combination of the "ultrasensitivity" of current single analyte assay methods with the ability simultaneously to determine multiple analytes in the same sample represents, in my view, the next major methodological challenge in this field, and--if successfully addressed--will constitute a quantum advance on present analytical methods. Indeed the development of miniaturised multianalyte binding assay techniques may ultimately comes to be seen as analagous to, for example, the introduction of the word processor, and other similar major technological advances of the past decade.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Ekins. 1994. Immunoassay: recent developments and future directions.. https://doi.org/10.1016/0969-8051(94)90073-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.

The fate of the neutralizing antibody (NAB) in MS patients treated with interferons remains unclear. We conducted a follow-up survey of NAB titers in 59 long-term treated patients from the London and Vancouver cohorts of the pivotal trial of interferon alpha-1b. NAB were measured with the myxovirus protein A assay and an ELISA, at a mean follow-up that exceeded 8 years. NAB disappeared in the majority of patients.

Antigen-Antibody Reactions

[Cellular and molecular bases of allergic diseases of the conjunctiva].

The authors review the clinical signs of the five most frequent allergic diseases of the conjunctiva (seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal conjunctivitis, atopic conjunctivitis and giant papillary conjunctivitis), and then the immunologic bases of the development of the early-type allergic reaction. In the course of this, they describe the roles played by IgE globulin and the mastocytes in histamine release, and also the possible effects manifested in allergic inflammation in consequence of the metabolic products of arachidonic acid formed in the cell membrane (leukotrienes, lipoxins, prostaglandins and thromboxanes). Following this, they present an account of the process by which the eosinophilic cells that play the main role in the later stages of allergic inflammation emerge from te vascular bed, and the effects of various adhesion molecules. Finally, they discuss a new classification of conjunctivitis (proposed by Bonini), based on the pathomechanisms of the diseases.

Antigen-Antibody Reactions

Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure.

BACKGROUND: Autoantibodies against synthetic peptides of beta-adrenergic receptors have been observed in human cardiomyopathy. However, it has never been shown that such antibodies really interact with native human beta-adrenergic receptors, nor has the clinical impact of such an interaction been investigated in larger groups of patients. METHODS AND RESULTS: We screened 104 patients with dilated or ischemic cardiomyopathy (NYHA functional classes II to IV) and 108 healthy subjects for IgG antibodies reacting with beta-receptor peptides. Such IgGs were further analyzed for binding and functional interactions with native recombinant human beta-adrenergic receptors. Antibodies reacting with synthetic receptor peptides were present in 51% of the patients. However, only a subgroup directed against the second extracellular receptor domain also recognized native human beta-adrenergic receptors situated in a cell membrane. All antibodies of this subgroup impaired receptor ligand binding and enhanced receptor-mediated signaling, which could be blocked by 5 micromol/L bisoprolol in vitro. Their prevalence was 1% in healthy subjects and 10% in ischemic cardiomyopathy, whereas it amounted to 26% in dilated cardiomyopathy and was associated with a significantly poorer left ventricular function. CONCLUSIONS: Our data show that activating autoantibodies against human beta-adrenergic receptors exist in approximately 25% of patients with dilated cardiomyopathy. Counteraction of such autoantibodies might contribute to the beneficial effects of beta-adrenergic receptor blockade in chronic heart failure.

Antigen-Antibody Reactions